All In Biotech

Drug Trial Radar · NCT07234474

A Phase I Study of YK012 in Primary Membranous Nephropathy

A Phase I Study of YK012, a Humanized CD19 × CD3 Bispecific Antibody, in Participants With Very High-Risk, Refractory Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Sep 2027

Primary completion

Oct 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).

Conditions

  • Primary Membranous Nephropathy

Interventions

  • YK012Drug

    YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ia: Dose-Limiting Toxicity (DLT)Time frame: up to 28 days after the first dose
  2. Adverse Event (AE)Time frame: From the first induction to the end of the trial at 53 weeks
  3. Severe Adverse EventTime frame: From the first induction to the end of the trial at 53 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.